Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Accurate Diagnosis of High-Risk Pulmonary Nodules Using a Non-Invasive Epigenetic Biomarker Test

Tuesday, March 11, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a paper on a non-invasive epigenetic biomarker test for accurately diagnosing high-risk pulmonary nodules. This innovative approach may enhance diagnostic precision and contribute to better cancer detection. The research highlights the potential of epigenetic markers in clinical applications, particularly in oncology.
Price reaction · baseline $11.6 (2025-03-10 close) · hit pre-market · 4 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
+1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Non-invasive method for diagnosing high-risk pulmonary nodules.
  • Utilizes epigenetic biomarkers, potentially improving diagnostic accuracy.
  • Contributes to advancements in cancer detection technologies.

Full Press Release Details

Paper titled: Accurate Diagnosis of High-Risk Pulmonary Nodules Using a Non-Invasive Epigenetic Biomarker Test
Pei-Hsing Chen, Tung-Ming Tsai, Tzu-Pin Lu, Hsiao-Hung Lu, Dorian Pamart, Aristotelis Kotronoulas, Marielle Herzog, Jacob Vincent Micallef, Hsao-Hsun Hsu, and Jin-Shing Chen 2
Published on MDPI

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the published paper?

The paper focuses on a non-invasive epigenetic biomarker test for diagnosing high-risk pulmonary nodules.

How does the test improve diagnosis?

The test utilizes epigenetic biomarkers, potentially enhancing the accuracy of cancer detection.

Who are the authors of the study?

The study is authored by Pei-Hsing Chen and several collaborators.

Where was the paper published?

The paper was published on MDPI.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare pulmonary nodules cancer diagnosis epigenetic biomarkers non-invasive testing
Last updated: Mar 11, 2025

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk